Newsfeeds - Spark Newswire

2 minute read

Obseva Announced FDA Acceptance of NDA for Linzagolix

Today, 6:49 AM

Obseva SA (NASDAQ: OBSV), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today announced that the New Drug Application (NDA) for linzagolix for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women has been accepted

OBSV

2 minute read

24 Stocks Moving in Thursday’s Pre-Market Session

By Lisa Levin

Today, 6:49 AM

Gainers Evaxion Biotech A/S (NASDAQ: EVAX) rose 143.5% to $15.83 in pre-market trading after dropping over 10% on Wednesday.

ARTL

4 minute read

The Daily Biotech Pulse: Novavax Retreats Amid Vaccine Issues, LumiraDx COVID Test Approved In India, Sesen Shines On Positive Bladder Cancer Review

By Shanthi Rexaline

Today, 6:49 AM

Here's a roundup of top developments in the biotech space over the last 24 hours.

ABT

1 minute read

ObsEva Presents Linzagolix Data From Uterine Fibroid Trials

By Vandana Singh

Today, 6:49 AM

ObsEva SA (NASDAQ: OBSV) has announced data from PRIMROSE (1 and 2) Phase 3 study of linzagolix for uterine fibroids.

OBSV

4 minute read

The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal

By Shanthi Rexaline

Today, 6:49 AM

Here's a roundup of top developments in the biotech space over the last 24 hours.

ATRA

7 minute read

The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs

By Shanthi Rexaline

Today, 6:49 AM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14)

ACAD

3 minute read

26 Stocks Moving in Wednesday’s Pre-Market Session

By Lisa Levin

Today, 6:49 AM

Gainers Nxt-ID, Inc. (NASDAQ: NXTD) rose 46.1% to $0.6699 in pre-market trading after dropping 11% on Tuesday.

ATNX

2 minute read

ObsEva Announced Submission of New Drug Application to FDA for Linzagolix for the Treatment of Uterine Fibroids

By Charles Gross

Today, 6:49 AM

ObsEva SA (NASDAQ: OBSV) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for linzagolix for the treatment of uterine fibroids.

OBSV

6 minute read

The Daily Biotech Pulse: Pfizer’s Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings

By Shanthi Rexaline

Today, 6:49 AM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3)

ABSI

1 minute read

Pre-Market Outlook

Benzinga Pro’s Top 5 Stocks To Watch For Wednesday, Jul. 7, 2021: OSAT, AMZN, DIS, SVOK, OBSV

By Benzinga Newsdesk

Today, 6:49 AM

Today's 5 Stock Ideas Orbsat (OSAT) - The most-searched ticker on Benzinga Pro over the last 24 hours. The stock closed up more than 50% on Tuesday; the Benzinga newsdesk did not see new to justify the move

AMZN